The MARECA (national Study of Management of Breast Cancer Locoregional Recurrence and Oncological Outcomes) Study: Protocol for a Prospective, Multicentre Cohort Study

Overview

Journal Int J Surg Protoc

Specialty General Surgery

Date 2024 Mar 4

PMID 38433867

Authors

Sue M Hartup

Jenna L Morgan

Vinton Wt Cheng

Peter A Barry

Ellen Copson

Ramsey I Cutress

Rajiv Dave

Beatrix Elsberger

Patricia Fairbrother

Brian Hogan

Kieran Horgan

Cliona C Kirwan

Stuart A McIntosh

Rachel L OConnell

Neill Patani

Shelley Potter

Tim Rattay

Lisa Sheehan

Lynda Wyld

Baek Kim

Affiliations

Soon will be listed here.

Abstract

Background: Despite a UK 5-year breast cancer survival rate of 86.6%, patients may develop breast cancer recurrence within the same breast after breast conserving surgery, as well as in the remaining skin or chest wall after mastectomy or in the ipsilateral lymph glands. These recurrences, collectively termed locoregional recurrence (LRR), occur in around 8% of patients within 10 years of their original diagnosis. Currently, there is a lack of robust information on the presentation and prevalence of LRR with no UK-specific clinical guidelines available for the optimal management of this patient group. Additionally, there is a need to identify patterns of LRR presentation and their progression, which will enable prognostic factors to be determined. This will subsequently enable the tailoring of treatment and improve patient outcome.

Methods: The MARECA study is a prospective, multicentre cohort study recruiting patients diagnosed with breast cancer LRR +/- associated distant metastases. Over 50 UK breast units are participating in the study with the aim of recruiting at least 500 patients over a recruitment period of 24 months. The data collected will detail the tumour pathology, imaging results, surgical treatment, radiotherapy and systemic therapy of the primary and recurrent breast cancer. Study follow-up will be for up to 5 years following LRR diagnosis to determine subsequent oncological outcomes and evaluate potential prognostic factors.

Discussion: This study will address the current knowledge gap and identify subgroups of patients who have less successful treatment outcomes. The results will determine the current management of LRR and the prognosis of patients diagnosed with breast cancer LRR +/- distant metastases in the UK, with the aim of establishing best practice and informing future national guidelines. The results will direct future research and inform the design of additional interventional trials and translational studies.

Citing Articles

Surgical Management and Its Impact on Adjuvant Treatment in Recurrent Ipsilateral Breast Cancer: A Retrospective Cohort Study.

Torras I, Cebrecos I, Castillo H, Rodriguez L, Zaragoza-Ballester P, Sitges C J Clin Med. 2024; 13(17).

PMID: 39274355 PMC: 11396610. DOI: 10.3390/jcm13175142.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Wapnir I, Price K, Anderson S, Robidoux A, Martin M, Nortier J . Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. 2018; 36(11):1073-1079. PMC: 5891132. DOI: 10.1200/JCO.2017.76.5719. View

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

Brunt A, Haviland J, Wheatley D, Sydenham M, Alhasso A, Bloomfield D . Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020; 395(10237):1613-1626. PMC: 7262592. DOI: 10.1016/S0140-6736(20)30932-6. View

Yi M, Buchholz T, Meric-Bernstam F, Bedrosian I, Hwang R, Ross M . Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011; 253(3):572-9. PMC: 4331097. DOI: 10.1097/SLA.0b013e318208fc2a. View

Laird J, Lok B, Siu C, Cahlon O, Khan A, McCormick B . Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Ann Surg Oncol. 2017; 25(1):154-163. PMC: 5827945. DOI: 10.1245/s10434-017-6209-4. View

Courtney A, OConnell R, Rattay T, Kim B, Cutress R, Kirwan C . The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol. Int J Surg Protoc. 2020; 24:1-5. PMC: 7388760. DOI: 10.1016/j.isjp.2020.07.003. View

Wong S, Golshan M . Management of In-Breast Tumor Recurrence. Ann Surg Oncol. 2018; 25(10):2846-2851. DOI: 10.1245/s10434-018-6605-4. View

Morgan J, Cheng V, Barry P, Copson E, Cutress R, Dave R . The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National practice questionnaire of United Kingdom multi-disciplinary decision making. Eur J Surg Oncol. 2022; 48(7):1510-1519. DOI: 10.1016/j.ejso.2022.03.017. View

10.

Potter S, Fairhurst K, Cowan K, Vincent S, Lewis I, Cutress R . Identifying research priorities in breast cancer surgery: a UK priority setting partnership with the James Lind Alliance. Breast Cancer Res Treat. 2022; 197(1):39-49. PMC: 9628302. DOI: 10.1007/s10549-022-06756-4. View

11.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

12.

Marmot M, Altman G, Cameron D, Dewar J, Thompson S, Wilcox M . Independent UK Panel on Breast Cancer Screening replies to Michael Baum. BMJ. 2013; 346:f873. DOI: 10.1136/bmj.f873. View

13.

Bollet M, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel J . High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst. 2007; 100(1):48-58. DOI: 10.1093/jnci/djm266. View

14.

Potter S, Conroy E, Cutress R, Williamson P, Whisker L, Thrush S . Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study. Lancet Oncol. 2019; 20(2):254-266. PMC: 6358590. DOI: 10.1016/S1470-2045(18)30781-2. View

15.

Lips E, Kumar T, Megalios A, Visser L, Sheinman M, Fortunato A . Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nat Genet. 2022; 54(6):850-860. PMC: 9197769. DOI: 10.1038/s41588-022-01082-3. View

16.

OConnell R, Baker E, Trickey A, Rattay T, Whisker L, Macmillan R . Current practice and short-term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study. Br J Surg. 2018; 105(13):1778-1792. DOI: 10.1002/bjs.10959. View

17.

McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935):2127-35. PMC: 5015598. DOI: 10.1016/S0140-6736(14)60488-8. View

18.

Vaidya J, Massarut S, Vaidya H, Alexander E, Richards T, Caris J . Rethinking neoadjuvant chemotherapy for breast cancer. BMJ. 2018; 360:j5913. DOI: 10.1136/bmj.j5913. View

19.

Whitehead I, Irwin G, Bannon F, Coles C, Copson E, Cutress R . The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. BMC Cancer. 2021; 21(1):90. PMC: 7825231. DOI: 10.1186/s12885-020-07757-6. View

20.

Coles C, Griffin C, Kirby A, Titley J, Agrawal R, Alhasso A . Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017; 390(10099):1048-1060. PMC: 5594247. DOI: 10.1016/S0140-6736(17)31145-5. View